---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-091319"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T10:38:20.453279+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech Q2 net revenue $17.4M (+40% QoQ); DFD-29 Phase 3 positive, cosibelimab PDUFA Jan 2024

## Summary
- Total net revenue $17.4M in Q2 2023, a 40% increase from $12.4M in Q1 2023; dermatology products contributed $17.0M.
- DFD-29 Phase 3 trials for rosacea met co-primary and all secondary endpoints vs placebo and Oracea; NDA submission expected H2 2023.
- Cosibelimab BLA accepted with PDUFA date Jan 3, 2024; new longer-term data showed 55% ORR and 23% CR in locally advanced cSCC.
- Cash, equivalents and restricted cash $89.2M at June 30, 2023, down from $181.0M at Dec 31, 2022.
- Bylaws amended to clarify stockholder voting majority requirement; effective August 10, 2023.

## SEC filing metadata
- accession: 0001104659-23-091319
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000110465923091319/0001104659-23-091319-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000110465923091319/tm2323520d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-091319
- JSON: https://secwatch.observer/filing/0001104659-23-091319.json
- Plain text: https://secwatch.observer/filing/0001104659-23-091319.txt

## Key facts
- Earnings Releases
  Fortress Biotech, Inc. reported second quarter ended June 30, 2023 results: revenue $17.4 million.
  - Period: second quarter ended June 30, 2023
  - Revenue: $17.4 million
  - Result: reported results
  source text: Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1429260/000110465923091319/0001104659-23-091319-index.htm
- Governance Changes
  Fortress Biotech, Inc.: Amendment to Article II, Section 7 of the bylaws changing the voting requirement for stockholder actions (effective 2023-08-10).
  - Change: bylaw amendment
  - Effective: 2023-08-10
  source text: the affirmative vote of a majority of the shares of stock present or represented at the meeting, by ballot, proxy or electronic ballot, unless a different or minimum vote is required by the Certificate of Incorporation, these Bylaws, the Delaware General Corporate Law, the rules or regulations of any stock exchange applicable to the corporation, or any law or regulation applicable to the corporation or its securities, in which case such different or minimum vote shall be the required vote on the matter.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1429260/000110465923091319/0001104659-23-091319-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.